People with heart disease who took a drug called evolocumab had more heart-related deaths than those who took a dummy pill, according to a reanalysis of a major study — but the difference wasn’t...
Strongly supported
Multiple high-quality studies back this claim.
Not medical advice. For informational purposes only. Always consult a healthcare professional.
People with heart disease who took a drug called evolocumab had more heart-related deaths than those who took a dummy pill, according to a reanalysis of a major study — but the difference wasn’t...
See the technical phrasing
In patients with established atherosclerotic cardiovascular disease, treatment with the PCSK9 inhibitor evolocumab is associated with a numerically higher incidence of cardiac death compared to placebo, with 113 cardiac deaths in the evolocumab group versus 88 in the placebo group (relative risk 1.28, 95% confidence interval 0.97–1.69, p=0.078), based on independent readjudication of cause-of-death narratives from the FOURIER trial’s Clinical Study Report.
What the research says
Supports
1 study
Study: Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data
This study provides evidence supporting the claim.
Contradicts
0 studies
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies